Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
| LPTX Stock | USD 0.37 0.02 5.13% |
Slightly above 62% of Leap Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Leap Therapeutics suggests that many traders are alarmed. Leap Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Leap Therapeutics' earnings reports, geopolitical events, and overall market trends.
Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of the DeFianCe study evaluating DKN-01, Leaps anti-Dickkopf-1 antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer .
Read at finance.yahoo.com
 |
Leap Therapeutics Fundamental Analysis
We analyze Leap Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Leap Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Leap Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Leap Therapeutics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Leap Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Leap Therapeutics stock to make a market-neutral strategy. Peer analysis of Leap Therapeutics could also be used in its relative valuation, which is a method of valuing Leap Therapeutics by comparing valuation metrics with similar companies.
Peers
Leap Therapeutics Related Equities
| XFOR | X4 Pharmaceuticals | 8.31 | ||||
| ELEV | Elevation Oncology | 3.33 | ||||
| ABOS | Acumen Pharmaceuticals | 2.94 | ||||
| HOOK | Hookipa Pharma | 1.90 | ||||
| TERN | Terns Pharmaceuticals | 1.66 | ||||
| MREO | Mereo BioPharma | 0.91 | ||||
| DAWN | Day One | 0.16 | ||||
| INZY | Inozyme Pharma | 0.25 | ||||
| PDSB | PDS Biotechnology | 4.20 |
Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.